Taylor H Schreiber - JoVE Visualize

Showing results (11-20 of 31) with videos related to

Pageof 4

Sort By:

Cancer Immunology Research|July 2, 2016

Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor EliminationGeorge Fromm, Suresh de Silva, Louise Giffin, et al.

Journal for Immunotherapy of Cancer|December 20, 2018

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapyGeorge Fromm, Suresh de Silva, Kellsey Johannes, et al.

Transplantation|August 21, 2012

Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survivalDietlinde Wolf, Taylor H Schreiber, Panagiotis Tryphonopoulos, et al.

Journal of Immunology (Baltimore, Md. : 1950)|January 16, 2013

Cloning, expression, and functional characterization of TL1A-IgSamia Q Khan, Matthew S Tsai, Taylor H Schreiber, et al.

Cancer Immunology, Immunotherapy : CII|July 10, 2012

B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretionYu Zhang, Yair Eliav, Seung-Uon Shin, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015

Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer AgentsGeorge Dranitsaris, Roger B Cohen, Gary Acton, et al.

Blood|October 4, 2008

Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCTAllison L Bayer, Monica Jones, Jackeline Chirinos, et al.

Cancer Immunology Research|December 20, 2019

CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive ImmunitySuresh de Silva, George Fromm, Casey W Shuptrine, et al.

Human Molecular Genetics|November 28, 2015

Disruption of polycystin-L causes hippocampal and thalamocortical hyperexcitabilityGang Yao, Chong Luo, Michael Harvey, et al.

Inflammatory Bowel Diseases|June 27, 2026

Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel diseaseMahmud Hussain, Anne Y Lai, Derek Franklin, et al.

Pageof 4

Showing results (11-20 of 31) with videos related to

Sort By:

Pageof 4

Cancer Immunology Research|July 2, 2016

Gp96-Ig/Costimulator (OX40L, ICOSL, or 4-1BBL) Combination Vaccine Improves T-cell Priming and Enhances Immunity, Memory, and Tumor EliminationGeorge Fromm, Suresh de Silva, Louise Giffin, et al.

Journal for Immunotherapy of Cancer|December 20, 2018

Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapyGeorge Fromm, Suresh de Silva, Kellsey Johannes, et al.

Transplantation|August 21, 2012

Tregs expanded in vivo by TNFRSF25 agonists promote cardiac allograft survivalDietlinde Wolf, Taylor H Schreiber, Panagiotis Tryphonopoulos, et al.

Journal of Immunology (Baltimore, Md. : 1950)|January 16, 2013

Cloning, expression, and functional characterization of TL1A-IgSamia Q Khan, Matthew S Tsai, Taylor H Schreiber, et al.

Cancer Immunology, Immunotherapy : CII|July 10, 2012

B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretionYu Zhang, Yair Eliav, Seung-Uon Shin, et al.

Journal of Immunotherapy (Hagerstown, Md. : 1997)|August 12, 2015

Statistical Considerations in Clinical Trial Design of Immunotherapeutic Cancer AgentsGeorge Dranitsaris, Roger B Cohen, Gary Acton, et al.

Blood|October 4, 2008

Host CD4+CD25+ T cells can expand and comprise a major component of the Treg compartment after experimental HCTAllison L Bayer, Monica Jones, Jackeline Chirinos, et al.

Cancer Immunology Research|December 20, 2019

CD40 Enhances Type I Interferon Responses Downstream of CD47 Blockade, Bridging Innate and Adaptive ImmunitySuresh de Silva, George Fromm, Casey W Shuptrine, et al.

Human Molecular Genetics|November 28, 2015

Disruption of polycystin-L causes hippocampal and thalamocortical hyperexcitabilityGang Yao, Chong Luo, Michael Harvey, et al.

Inflammatory Bowel Diseases|June 27, 2026

Preclinical development of SL-325, a novel high-affinity DR3-blocking antibody for durable inhibition of the DR3/TL1A axis in inflammatory bowel diseaseMahmud Hussain, Anne Y Lai, Derek Franklin, et al.

Pageof 4